Central Nervous System Studies

A group of wholly-owned investigative sites managed by full time Principal Investigators and Clinical Site Directors with extensive clinical trials research experience, particularly in the area of central nervous system drugs. These Investigators collaboratively have conducted the most central nervous system (CNS) research in the industry.

7 Industry-leading clinics with collective experience in over 600 Phase I-IV clinical trials involving 8,500+ patients

The Radiant Research CNS investigator sites provide pharmaceutical and biotechnology sponsors with rapid study startup, reliable enrollment in disease state populations, and the highest quality data for all phases of clinical trials in central nervous system patient populations.

Each of the CNS investigator sites is built around a highly experienced Principal Investigator and Site Director team with well-trained Clinical Coordinators and support staff.  Sub-Investigators extend the medical coverage and therapeutic reach of the site and Community Service Liaisons bolster enrollment and facilitate study completion.

Centralized budgeting and contracting and use of central IRB facilitate study startup and allow the clinical team to focus on enrollment and study conduct.  Wrapped around the team is an industry-leading Quality Assurance program lead by a national Vice President for QA who coordinates bi-annual audits and ensures adherence to Standard Operating Procedures.

Our centers offer both inpatient and outpatient capabilities along with an extensive list of indications, including:

  • ADHD
  • Addiction medicine (alcohol, opioid use, cocaine, heroin)
  • Anxiety Disorders
  • Biploar (Type I, II, depression, mania)
  • Depression
  • Memory disorders (Alzheimer’s Disease, mild cognitive impairment)
  • Phase I disease state (schizophrenia, bipolar, depression/anxiety, Alzheimer’s Disease)
  • Pain (DPN, PHN, chronic, fibromyalgia, migrane)
  • Schizophrenia
  • Sexual dysfunction (male and female)
  • Sleep
  • Smoking cessation
  • Bethany Davis, MD – board certified psychiatrist –  Atlanta, GA
  • Morteza Marandi, MD – board certified psychiatrist  – Cerritos, CA
  • Aggy Vallanat, MD – board certified psychiatrist  – Queens, NY
  • Adam Lowy, MD – board certified psychiatrist  – Washington, DC
  • Thomas Weiss, MD – board certified psychiatrist – San Antonio, TX
  • Mark A. Johnston, MD – board certified psychiatrist – Salt Lake City, UT
  • William Grainger, MD & Jeffrey Shy, MD – Neurologists – Gilbert, AZ
  • Large database for schizophrenia, bipolar disorder, and depression
  • At or near major mental health facilities to facilitate enrollment
  • Inpatient facilities for psychosis and other acute states
  • Outpatient facilities for stable patients
  • Phase I studies in moderate to severe mental illness
  • Every neuropsychiatric and cognitive assessment available
  • Single point of contact for budget and contracting
  • Central IRB for all inpatient and outpatient studies
  • Central coordination of advertising approval and placement
  • Numerous successful sponsor and FDA audits.
  • Corporate driven Quality Assurance program with bi-annual on-site audits
  • Fully-developed and regularly-updated SOPs consistent across all sites

Contact Our CNS Sites